CA$0.006 (vs CA$0.018 in 1Q 2024)

• Revenue: CA$6.04m (down 28% from 1Q 2024).

• Net income: CA$857.0k (down 65% from 1Q 2024).

• Profit margin: 14% (down from 29% in 1Q 2024). The decrease in margin was driven by lower revenue.

• EPS: CA$0.006 (down from CA$0.018 in 1Q 2024).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Looking ahead, revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 59% growth forecast for the Biotechs industry in Canada.

Performance of the Canadian Biotechs industry.

The company’s shares are up 11% from a week ago.

Don’t forget that there may still be risks. For instance, we’ve identified 3 warning signs for Microbix Biosystems that you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.